Urolog. pro Praxi, 2008; 9(6): 316-322

Fesoterodin - nové anticholinergikum pro léčbu hyperaktivního močového měchýře

doc. MUDr. Roman Zachoval Ph.D
Urologické oddělení, Fakultní Thomayerova nemocnice Praha

Autor v přehledném článku referuje o fesoteridinu, novém antimuskariniku, které funkčně účinkuje jako proléčivo. Rychle a extenzivně se hydrolyzuje v těle všudypřítomnými nespecifickými esterázami na 5-hydroxymetyltolterodin, což je aktivní matabolit zodpovědný za veškerou antimuskarinovou aktivitu. Přeměna fesoterodinu na aktivní metabolit tak na rozdíl od svého farmakologického předchůdce tolterodinu obchází dráhu jaterního enzymatického systému CYP, který může mít individuálně velmi rozdílnou aktivitu.

Keywords: fesoterodin, anticholinergikum, hyperaktivní močový měchýř

Published: January 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zachoval R. Fesoterodin - nové anticholinergikum pro léčbu hyperaktivního močového měchýře. Urol. praxi. 2008;9(6):316-322.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Cole P. Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: A safety update. Drugs Future 2004; 29(7): 715-720. Go to original source...
    2. Chapple C, van Kerrebroeck P, Tubaro A, Haag-Molkenteller C, Forst H-T, Massow U, et al. Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol 2007; 52(4): 1204-1212. Go to original source... Go to PubMed...
    3. Khullar V, Rovner E, Dmochowski R, Nitti V, Wang J, Guan Z. Fesoterodine dose response in subjects with overactive bladder syndrome. Urol 2008; 71(5): 839-843. Go to original source... Go to PubMed...
    4. Michel MC. Fesoterodine: a novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9(10): 1787-1796. Go to original source... Go to PubMed...
    5. Ney P, Pandita RK, Newgreen DT, Breidenbach A, Stohr T, Andersson KE. Pharmacological characterization of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 2008; 101(8): 1036-1042. Go to original source... Go to PubMed...
    6. Nitti VW, Dmochowski R, Sand PK, Forst HT, Haag-Molkenteller C, Massow U, Wang J, Brodsky M, Bavendam T. Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. Urol 2007; 178(6): 2488-2494. Go to original source... Go to PubMed...
    7. Toviaz(R) Summary of Product Characteristics.
    8. Williams FM. Clinical significance of esterases in man. Clinical Pharmacokinetics 1985; 10: 392-403. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.